Neovacs (ALNEV) | Stock Overview & Key Data
Neovacs | Small-cap | Healthcare
Neovacs | Small-cap | Healthcare
Neovacs Performance Comparison
Stock Range
Today's Range
Low: €0.78
High: €0.86
on August 8, 2025
52 Week Range
Low: €0.78
High: €83,000.00
on August 8, 2025
All-Time High: €2.00 on July 17, 2025
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€483.4K
EPS
-216.07
P/E Ratio (TTM)
0.00
Forward P/E
9.90
P/B Ratio
0.01
PEG Ratio
9.90
Div. Yield
N/A
ROE
-98.39%
Beta
-56.946
Debt to Equity
1.28
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-7,356.60%
Profit Margin
11.58%
Returns and Earnings
Return on Assets (TTM)
-11.09%
Return on Equity (TTM)
-98.39%
EBITDA
€-6.4M
Net Income (TTM)
€-32.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€1.61
Quarterly Revenue Growth (YoY)
-90.40%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Neovacs ALNEV | 483.42K Small-cap | -6.59% | -61.36% | -61.36% | -61.36% | -61.36% | -57.50% | -57.50% | -57.50% |
| Abivax SA ABVX | 4.49B Large-cap | -5.31% | 791.18% | 913.38% | 961.30% | 732.42% | 474.95% | 572.59% | 214.97% |
| Valneva SE VLA | 546.93M Mid-cap | 9.79% | 50.21% | 22.53% | 14.70% | 55.41% | 11.58% | -65.68% | -34.65% |
| Ose OSE | 136.49M Small-cap | -6.72% | 20.61% | -0.67% | -6.57% | -20.72% | -14.55% | -15.74% | 6.14% |
| Transgene S.A TNG | 133.40M Small-cap | 3.00% | 30.38% | 68.85% | 49.28% | 51.47% | 3.00% | -53.60% | -29.93% |
| Adocia S.A ADOC | 126.07M Small-cap | -7.12% | 81.20% | 65.84% | 18.75% | 3.42% | 16.06% | 27.88% | -18.70% |
Ownership & Short Interest
Insider Ownership
0.00%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
29K
Average 90-Day Volume
20K
Neovacs Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Neovacs would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALNEV's 52-week high and low?
- In the last 52 weeks, Neovacs reached a high of €83,000.00 (on N/A) and a low of €0.78 (on August 8, 2025).
- What is the market cap and P/E ratio for ALNEV?
- Curious about Neovacs's size and valuation? Its market capitalization stands at 483.42K. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.00, and the forward P/E (looking ahead) is 9.90.
- Does ALNEV pay dividends? If so, what's the yield?
- As for dividends, Neovacs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Neovacs's main competitors or similar companies to consider before investing?
When looking at Neovacs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX4.49B Healthcare Biotechnology 474.95% 572.59% Valneva SE
VLA546.93M Healthcare Biotechnology 11.58% -65.68% Ose
OSE136.49M Healthcare Biotechnology -14.55% -15.74% Transgene S.A
TNG133.40M Healthcare Biotechnology 3.00% -53.60% Adocia S.A
ADOC126.07M Healthcare Biotechnology 16.06% 27.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Neovacs? (e.g., ROE, Debt/Equity)
- To get a sense of Neovacs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -98.39%, the Debt to Equity ratio from the most recent quarter is 1.28, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ALNEV?
- Looking at Neovacs's growth, its revenue over the trailing twelve months (TTM) was €434K. Compared to the same quarter last year (YoY), quarterly revenue grew by -90.40%, and quarterly earnings saw a YoY growth of N/A.
- How much of ALNEV stock is held by insiders and institutions?
- Wondering who owns Neovacs stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.